SPEX - Spherix Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.50
-0.02 (-1.32%)
At close: 4:00PM EDT

1.55 +0.06 (4.03%)
After hours: 4:05PM EDT

Stock chart is not supported by your current browser
Previous Close1.52
Open1.51
Bid1.49 x 400
Ask1.55 x 300
Day's Range1.49 - 1.60
52 Week Range0.83 - 4.75
Volume128,951
Avg. Volume482,723
Market Cap9.34M
Beta-1.43
PE Ratio (TTM)-1.00
EPS (TTM)-1.51
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date1980-05-12
1y Target Est19.00
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    Hoth Therapeutics Inc. Announces the Addition of Dr. Richard D Granstein, M.D. to the Company's Technology Advisory Board

    NEW YORK, Oct. 16, 2017 /PRNewswire/ -- Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or  the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today the addition of Dr. Richard D. Granstein, M.D., to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in developing the BioLexa Platform.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

  • PR Newswirelast month

    Hoth Therapeutics Inc. Announces the Addition of Dr. Andrew Herr to the Company's Technology Advisory Board

    NEW YORK, Sept. 5, 2017 /PRNewswire/ -- Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today the addition of Dr. Andrew Herr, PhD, to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in developing the BioLexa Platform.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

  • Spherix Announces the Addition of Dr. Scott T. Tagawa to Company's Technology Advisory Board
    PR Newswire2 months ago

    Spherix Announces the Addition of Dr. Scott T. Tagawa to Company's Technology Advisory Board

    NEW YORK, Aug. 15, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to the fostering of technology, today announced the addition of Dr. Scott T. Tagawa to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena. Dr. Scott T. Tagawa, MD, MS is the Richard A. Stratton Associate Professor in Hematology and Oncology and an Associate Professor of Clinical Medicine and of Clinical Urology at Weill Cornell Medicine.

  • Spherix Issues Letter to Shareholders
    PR Newswire3 months ago

    Spherix Issues Letter to Shareholders

    NEW YORK, Aug. 2, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to fostering of technology, today issued a letter to shareholders. It is with great pleasure that I take this opportunity to update you on recent events at the Company and describe in greater detail our strategic path forward.   The fundamentals at Spherix are stronger than they have been in recent memory and our path to value creation is moving forward with precision and focus.

  • Spherix Announces That Anthony Hayes Joins the Board of Directors at Hoth Therapeutics Inc.
    PR Newswire3 months ago

    Spherix Announces That Anthony Hayes Joins the Board of Directors at Hoth Therapeutics Inc.

    NEW YORK, July 27, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to fostering of technology, today announced that Anthony Hayes, CEO of Spherix Inc., joins the board of directors at Hoth Therapeutics Inc.

  • Spherix Announces the Formation of a Technology Advisory Board in Area of BioPharmaceutical Opportunities
    PR Newswire3 months ago

    Spherix Announces the Formation of a Technology Advisory Board in Area of BioPharmaceutical Opportunities

    NEW YORK, July 25, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to the fostering of technology, today announced the formation of a Technology Advisory Board in the area of biopharmaceutical opportunities. The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena, as well as to advise the Company in its work with Hoth Therapeutics. As previously reported, the Company recently acquired a controlling interest in Hoth Therapeutics, a company involved in the development of a novel topical treatment for patients suffering from atopic dermatitis, such as eczema.  Individuals serving on the advisory board will provide the Company advice, support and technical assistance in reviewing diversification opportunities.

  • Spherix Announces Closing Of Public Offering Of Common Stock
    PR Newswire3 months ago

    Spherix Announces Closing Of Public Offering Of Common Stock

    NEW YORK, July 24, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to fostering of technology, today announced that it has closed its previously announced firm commitment underwritten public offering of 1,250,000 shares of its common stock at a price to the public of $2.00 per share. After deducting the underwriter's discount and other offering expenses payable by Spherix, the net proceeds to the Company are approximately $2.1 million.

  • Spherix Announces Pricing of Public Offering of Common Stock
    PR Newswire3 months ago

    Spherix Announces Pricing of Public Offering of Common Stock

    NEW YORK, July 19, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to fostering of technology and monetization of intellectual property, today announced that it has priced a firm commitment underwritten public offering of 1,250,000 shares of its common stock at a price to the public of $2.00 per share. In addition, Spherix has granted the underwriter a 45-day option to purchase up to 187,500 additional shares of common stock to cover over-allotments, if any.

  • Spherix Inc. Announces Closing of the Deal with Hoth Therapeutics
    PR Newswire4 months ago

    Spherix Inc. Announces Closing of the Deal with Hoth Therapeutics

    Spherix Incorporated Acquires 6,800,000 shares of Hoth Therapeutics NEW YORK , July 3, 2017 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) reported today, following the disclosure made June 20 th ...

  • PR Newswire4 months ago

    Spherix Issues Letter to Shareholders

    NEW YORK, June 27, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, today issued a letter to shareholders. With that in mind, I'm going to provide you with more information on the transaction and update you on why we believe this transaction has positioned Spherix for growth.  I want each of you to know that I see the fundamentals at Spherix stronger than at any time in the last few years and our path to value creation is moving forward with focus.

  • Spherix Inc. Announces Definitive Terms Reached to Acquire Controlling Interest in Hoth Therapeutics, a Biopharmaceutical Company Developing its BioLexa Platform to Treat Skin Illness Such as Eczema.
    PR Newswire4 months ago

    Spherix Inc. Announces Definitive Terms Reached to Acquire Controlling Interest in Hoth Therapeutics, a Biopharmaceutical Company Developing its BioLexa Platform to Treat Skin Illness Such as Eczema.

    Hoth's BioLexa platform uses its proprietary technology to treat eczema without the use of traditional topical steroids. NEW YORK, June 20, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) announced today that the Company has negotiated definitive terms to acquire a controlling interest in Hoth Therapeutics, a development stage biopharmaceutical company focused on the development of therapeutics for patients suffering from atopic dermatitis, such as eczema.  Closing of the deal with Hoth is subject to the completion and execution of customary closing documents, which the Company expects to be completed within 30 days or less.

  • Spherix, Inc. :SPEX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
    Capital Cube5 months ago

    Spherix, Inc. :SPEX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

    Categories: Yahoo FinanceGet free summary analysis Spherix, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Spherix, Inc. – RPX Corporation, FORM Holdings Corp., Acacia Research Corporation, Charter Communications, Inc. Class A and Lightbridge Corporation (RPXC-US, FH-US, ACTG-US, CHTR-US and LTBR-US) that have also reported ... Read more (Read more...)

  • Spherix Announces Economic Interest Acquired in New Patent Portfolio
    PR Newswire6 months ago

    Spherix Announces Economic Interest Acquired in New Patent Portfolio

    Spherix and its partner Equitable IP Corporation have acquired an economic interest and the right to monetize a valuable portfolio in the fiber optic technology space as part of their ongoing patent monetization efforts.

  • Spherix, Inc. :SPEX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017
    Capital Cube6 months ago

    Spherix, Inc. :SPEX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017

    Categories: Yahoo FinanceGet free summary analysis Spherix, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 0.31 million, Net Earnings of USD -3.90 million. Change in operating cash flow of 7.84% compared to same period last year is about the same as change in earnings, likely no significant movement ... Read more (Read more...)

  • Benzinga7 months ago

    Your Guide To Patent Play Exposure

    Litigations more often trigger strong stock moves, and this was evident in the rally by the shares of ParkerVision, Inc. (NASDAQ: PRKR ) last Wednesday. ParkerVision Goes 4 Up Over Qualcomm ParkerVision ...

  • PR Newswire8 months ago

    Spherix Announces New Clients in the $100B Online Learning Business

    NEW YORK, Feb. 21, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, today announced that it has signed up a new client to its Patent Monetization and Consulting subsidiary. Spherix has entered into an IP Consulting Services Agreement with Numedeon and VWIP Inc.  Numedeon Inc. is a privately held company based in Pasadena, California, that since 1999 has been developing immersive online digital learning technology.

  • PR Newswire9 months ago

    Spherix Updates Shareholders

    NEW YORK, Jan. 23, 2017 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, ...

  • PR Newswire11 months ago

    Spherix Executes Revenue Generating Agreement with LawCash

    NEW YORK, Nov. 28, 2016 /PRNewswire/ -- Spherix Incorporated (SPEX)  a company committed to the fostering of technology and monetization of intellectual property, today announced that it executed a Consulting Services Agreement with LawCash ®(www.lawcash.com), ("LawCash") one of the nation's largest pre-settlement funding companies.  Under the Consulting Services Agreement, Spherix will provide LawCash with consulting and managerial services, with the goal of growing both businesses, as well as exploring other opportunities for the two companies to work together. LawCash is a specialty finance company, concentrating in litigation funding and attorney financing services.  As one of the nation's leading providers of litigation financing, LawCash offers individual plaintiff funding and attorney funding before and after settlement or verdict.

  • PR Newswire11 months ago

    Spherix Signs New Client in the $3.5 Billion Vaporizer Business

    NEW YORK, Nov. 7, 2016 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, ...

  • PR Newswirelast year

    Spherix Announces Changes to Board of Directors

    NEW YORK, Oct. 31, 2016 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, ...